Sanofi news in 2026: 36 dated events
The latest Sanofi event on this page is dated Nov 4, 2026. lamarseillaise.fr reported: In Digne-les-Bains, FO warns about staff reductions at Sanofi and the hospital.
PublicPharmaceutical Manufacturing10,000+ employeessanofi.comLinkedIn
Get Sanofi's live signals in Claude or ChatGPT, or by API
What changed at Sanofi this week? Use Autobound signals for sanofi.com.- Dated events
- 36
- Last 90 days
- 26
- Latest
- Nov 4, 2026
Source: Autobound Signal API · 89 signals tracked for Sanofi · updated
News · latest 10
Latest Sanofi news
Showing 10 of 36 dated events. The Signal API returns all of them.
Get them with one API call- CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation IndexSanofi ranked first in the 2026 CNS Summit Digital Innovation Index.
- Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272With Nurix Therapeutics, Inc.
- Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeSanofi initiated a Phase 3 clinical trial in Europe evaluating an influenza-COVID-19 combination vaccine utilizing Novavax's Nuvaxovid and Sanofi's Efluelda/Fluzone High-Dose.
- Sanofi partners with the UAE to advance genomic research and health innovationWith Khalifa University
- Sanofi Stock: ScionxBio optimizes mRNA candidatesSanofi entered into a global collaboration and licensing agreement with ScionxBio to develop extended-exposure variants of selected mRNA candidates.
- ISPE Names Sanofi S.A. the 2026 ISPE Facility of the Year Awards (FOYA) Overall Winner for its Modulus ProjectSanofi S.A. was recognized as the FOYA Overall Winner of the 2026 ISPE Facility of the Year Awards for its Modulus project.
- Sanofi Exercises Option on Recursion's First Development Candidate, Triggering a $10 Million Milestone PaymentSanofi exercised its option on Recursion's first development candidate, advancing an oral small molecule for inflammatory diseases into its pipeline with Phase 1 trials expected in 2027.
- Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their CollaborationSanofi has optioned and added a potential first-in-class oral small molecule immunology development candidate to its development pipeline from its research collaboration with Recursion.
Showing 10 of 36 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Sanofi with the Signal API
One POST /v1/companies/enrich call with sanofi.com returns Sanofi news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"sanofi.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Sanofi news
What is the latest news on Sanofi?
What is going on with Sanofi?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .